Oscar R. Herrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oscar R. Herrera has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Brian M. Peters
Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center
2 shared publications - Gustavo Rey Alvira-Arill
Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA
2 shared publications - Jeremy S. Stultz
The University of Tennessee Health Science Center College of Pharmacy
2 shared publications Richard A. Helms
University of Tennessee Health Science Center, Memphis, USA
2 shared publications- Richard A. Helms
Department of Clinical Pharmacy, University of Tennessee Health Science Center College of Pharmacy, Memphis, Tennessee ; State of Tennessee Center of Excellence in Pediatric Pharmacokinetics and Therapeutics, Memphis, Tennessee ; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
2 shared publications - Ajay J. Talati
Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
1 shared publication
Latest Publications
- Open Access
- 9 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5) , 484
Heterogeneity of Biofilm Formation Among Staphylococcus aureus and Coagulase-Negative Staphylococcus Species in Clinically Relevant Intravenous Fat Emulsions
Background: Compared to soybean oil intravenous fat emulsion (SO-IFE), use of mixed-oil IFE (MO-IFE) is associated with reduced rates of catheter-related bloodstream infections caused by coagulase-negative Staphylococcus species (CoNS) in pediatric patients receiving parenteral nutrition. Methods: Using an in vitro biofilm model, this study aimed to assess the impact of IFEs on biofilm formation among Staphylococcus species. S. aureus, S. capitis, S. epidermidis, S. haemolyticus, S. hominis, and S. lugdunensis were cultivated as biofilms in media supplemented with SO-IFE, MO-IFE, or fish oil IFE (IFE). Biomass was quantified by the crystal violet method, and follow-up planktonic growth assays assessed antimicrobial effects of IFEs. Results: Compared to SO-IFE, MO-IFE and FO-IFE significantly inhibited biofilm formation of S. aureus but did not impact planktonic growth. Contrary to clinical data, CoNS biofilm formation was not impacted by any of the IFEs tested. S. aureus biofilm inhibition in IFEs was further investigated by comparing differences following growth in SO-IFE supplemented with capric acid, docosahexaenoic acid (DHA), or eicosapenaenoic acid (EPA) to concentrations matching those of MO-IFE. Capric acid supplementation was associated with significant reduction in biofilm formation compared to SO-IFE alone. However, this was attributed to a bactericidal effect based on follow-up planktonic growth assays. Conclusions: These results suggest that biofilm formation in S. aureus is variably impacted by fatty acid composition in clinically relevant IFEs, with capric acid exhibiting bactericidal activity against tested isolates.
- 9 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5) , 484
Open AccessHeterogeneity of Biofilm Formation Among Staphylococcus aureus and Coagulase-Negative Staphylococcus Species in Clinically Relevant Intravenous Fat Emulsions
Background: Compared to soybean oil intravenous fat emulsion (SO-IFE), use of mixed-oil IFE (MO-IFE) is associated with reduced rates of catheter-related bloodstream infections caused by coagulase-negative Staphylococcus species (CoNS) in pediatric patients receiving parenteral nutrition. Methods: Using an in vitro biofilm model, this study aimed to assess the impact of IFEs on biofilm formation among Staphylococcus species. S. aureus, S. capitis, S. epidermidis, S. haemolyticus, S. hominis, and S. lugdunensis were cultivated as biofilms in media supplemented with SO-IFE, MO-IFE, or fish oil IFE (IFE). Biomass was quantified by the crystal violet method, and follow-up planktonic growth assays assessed antimicrobial effects of IFEs. Results: Compared to SO-IFE, MO-IFE and FO-IFE significantly inhibited biofilm formation of S. aureus but did not impact planktonic growth. Contrary to clinical data, CoNS biofilm formation was not impacted by any of the IFEs tested. S. aureus biofilm inhibition in IFEs was further investigated by comparing differences following growth in SO-IFE supplemented with capric acid, docosahexaenoic acid (DHA), or eicosapenaenoic acid (EPA) to concentrations matching those of MO-IFE. Capric acid supplementation was associated with significant reduction in biofilm formation compared to SO-IFE alone. However, this was attributed to a bactericidal effect based on follow-up planktonic growth assays. Conclusions: These results suggest that biofilm formation in S. aureus is variably impacted by fatty acid composition in clinically relevant IFEs, with capric acid exhibiting bactericidal activity against tested isolates.
- 1 February 2025
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 30 (1) , 100-105
Use of Alternative Calcium Gluconate in Sodium Chloride Co-Infused With Parenteral Nutrition for Neonates and Infants During National Shortage
OBJECTIVE: The coronavirus pandemic led to many supply chain shortages including parenteral nutrition (PN) components, and for our institution, a critical shortage of calcium gluconate vials. Our institution switched to an alternative product, calcium gluconate in sodium chloride (Ca-gluconate-in-NaCl), and owing to lack of specific gravity data, it could not be placed as an additive in our compounder. Instead, it had to be used as a continuous infusion, co-infused with PN. The purpose of this study was to determine if the alternative product led to significant electrolyte abnormalities affecting calcium homeostasis in patients requiring PN. METHODS: This was a retrospective review of the electronic health record for all infants aged 0 days to 12 months from March 1, 2022, through May 31, 2022, who received PN and a continuous Ca-gluconate-in-NaCl infusion at our institution. Associations between dosing and adverse events were explored with ordinal and logistic regression. RESULTS: A total of 39 patients were included in our study. Ca-gluconate-in-NaCl was provided with PN for a median of 7 days. Hypocalcemia occurred in 16 of 39 (41%) study infants. Seven patients experienced mild hypocalcemia (8–8.5 mg/dL; p = 0.875), 7 experienced moderate hypocalcemia (7–7.9 mg/dL; p = 0.339), and 2 experienced severe hypocalcemia (<7 mg/dL; p = 0.214). One patient who experienced severe total serum hypocalcemia also experienced hypocalcemia as defined by ionized calcium concentrations (<1.1 mmol/L; p = 0.344). CONCLUSIONS: Ca-gluconate-in-NaCl infused via Y-site with PN could be a viable alternative during shortage of calcium gluconate vials for at least 7 days in infants requiring PN.
- 1 February 2025
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 30 (1) , 100-105
Use of Alternative Calcium Gluconate in Sodium Chloride Co-Infused With Parenteral Nutrition for Neonates and Infants During National Shortage
OBJECTIVE: The coronavirus pandemic led to many supply chain shortages including parenteral nutrition (PN) components, and for our institution, a critical shortage of calcium gluconate vials. Our institution switched to an alternative product, calcium gluconate in sodium chloride (Ca-gluconate-in-NaCl), and owing to lack of specific gravity data, it could not be placed as an additive in our compounder. Instead, it had to be used as a continuous infusion, co-infused with PN. The purpose of this study was to determine if the alternative product led to significant electrolyte abnormalities affecting calcium homeostasis in patients requiring PN. METHODS: This was a retrospective review of the electronic health record for all infants aged 0 days to 12 months from March 1, 2022, through May 31, 2022, who received PN and a continuous Ca-gluconate-in-NaCl infusion at our institution. Associations between dosing and adverse events were explored with ordinal and logistic regression. RESULTS: A total of 39 patients were included in our study. Ca-gluconate-in-NaCl was provided with PN for a median of 7 days. Hypocalcemia occurred in 16 of 39 (41%) study infants. Seven patients experienced mild hypocalcemia (8–8.5 mg/dL; p = 0.875), 7 experienced moderate hypocalcemia (7–7.9 mg/dL; p = 0.339), and 2 experienced severe hypocalcemia (<7 mg/dL; p = 0.214). One patient who experienced severe total serum hypocalcemia also experienced hypocalcemia as defined by ionized calcium concentrations (<1.1 mmol/L; p = 0.344). CONCLUSIONS: Ca-gluconate-in-NaCl infused via Y-site with PN could be a viable alternative during shortage of calcium gluconate vials for at least 7 days in infants requiring PN.
- 21 November 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (12) , 898-904
Comparison of catheter‐related bloodstream infection rates in pediatric patients receiving parenteral nutrition with soybean oil‐based intravenous fat emulsion versus a mixed oil fat emulsion
Study Objective: To compare rates of catheter‐related bloodstream infections (CR‐BSI) in pediatric patients who received parenteral nutrition (PN) with either soybean oil‐based intravenous fat emulsion (SO‐IFE) or mixed oil‐IFE (MO‐IFE). We hypothesized that the use of MO‐IFE would be independently associated with reduced infection rates compared with SO‐IFE.Design: Retrospective cohort study.Setting: Tertiary referral children's hospital and its associated gastrointestinal rehabilitation clinic (01 January, 2015–31 July, 2019).Patients: Days of IFE exposure were counted for patients aged Candida albicans, non‐albicans Candida spp., coagulase‐negative Staphylococcus (CoNS), Enterobacterales, methicillin‐resistant S. aureus, methicillin‐susceptible S. aureus, and Pseudomonadales. Average infection rate comparisons were quantified as incidence rate ratios (IRR) using generalized linear mixed modeling with a Poisson distribution.Main Results: Seven hundred and forty‐three SO‐IFE and 450 MO‐IFE exposures were reviewed from 1131 patients, totaling 37,599 and 19,796 days of therapy, respectively. From those found significantly different, the average rate of infections with CoNS was 3.58 (SE 0.5)/1000 days of SO‐IFE and 1.39 (SE 0.45)/1000 days of MO‐IFE (IRR [95% confidence interval, CI]: 0.27 [0.16–0.46]; p < 0.01). Total average rates of infection were 7.33 (SE 0.76)/1000 days of SO‐IFE and 4.52 (SE 0.75)/1000 days of MO‐IFE (IRR [95% CI]: 0.60 [0.44–0.81]; p < 0.01). Other factors associated with higher infection rates include female gender, neonatal age, and inpatient‐only IFE exposure.Conclusions: Receipt of MO‐IFE was associated with lower rates of CoNS and total CR‐BSIs compared with SO‐IFE in pediatric patients. These findings could have major implications on IFE selection for pediatric patients receiving PN.
- 21 November 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (12) , 898-904
Comparison of catheter‐related bloodstream infection rates in pediatric patients receiving parenteral nutrition with soybean oil‐based intravenous fat emulsion versus a mixed oil fat emulsion
Study Objective: To compare rates of catheter‐related bloodstream infections (CR‐BSI) in pediatric patients who received parenteral nutrition (PN) with either soybean oil‐based intravenous fat emulsion (SO‐IFE) or mixed oil‐IFE (MO‐IFE). We hypothesized that the use of MO‐IFE would be independently associated with reduced infection rates compared with SO‐IFE.Design: Retrospective cohort study.Setting: Tertiary referral children's hospital and its associated gastrointestinal rehabilitation clinic (01 January, 2015–31 July, 2019).Patients: Days of IFE exposure were counted for patients aged Candida albicans, non‐albicans Candida spp., coagulase‐negative Staphylococcus (CoNS), Enterobacterales, methicillin‐resistant S. aureus, methicillin‐susceptible S. aureus, and Pseudomonadales. Average infection rate comparisons were quantified as incidence rate ratios (IRR) using generalized linear mixed modeling with a Poisson distribution.Main Results: Seven hundred and forty‐three SO‐IFE and 450 MO‐IFE exposures were reviewed from 1131 patients, totaling 37,599 and 19,796 days of therapy, respectively. From those found significantly different, the average rate of infections with CoNS was 3.58 (SE 0.5)/1000 days of SO‐IFE and 1.39 (SE 0.45)/1000 days of MO‐IFE (IRR [95% confidence interval, CI]: 0.27 [0.16–0.46]; p < 0.01). Total average rates of infection were 7.33 (SE 0.76)/1000 days of SO‐IFE and 4.52 (SE 0.75)/1000 days of MO‐IFE (IRR [95% CI]: 0.60 [0.44–0.81]; p < 0.01). Other factors associated with higher infection rates include female gender, neonatal age, and inpatient‐only IFE exposure.Conclusions: Receipt of MO‐IFE was associated with lower rates of CoNS and total CR‐BSIs compared with SO‐IFE in pediatric patients. These findings could have major implications on IFE selection for pediatric patients receiving PN.
- 25 November 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 57 (1) , 61-68
Stability of 4 Intravenous Drug Formulations in Prefilled Syringes Stored Frozen for Up to 60 Days
Purpose: Prefilled drug syringe use may reduce the cost of routine antibiotic drug delivery. Storage of prefilled syringes frozen (−20°C) or refrigerated (4°C-5°C), can optimize the use of robotic syringe filling systems if acceptable stability data is gathered per USP 797 standards. Methods: Four intravenous (IV) drug formulations were prepared from bulk standard solutions and filled into 10 mL syringes using an Intellifill© IV Robot. Formulations were Piperacillin (2.0 g) and Tazobactam (0.25 g) as 2.25 g in 10 mL; Piperacillin (3.0 g) and Tazobactam (0.375 g) as 3.375 g in 10 mL; Cefuroxime as 1.5 g in 11 mL; and Vancomycin as 1.0 g in 10 mL. Concentrations were assayed at “zero time,” and after 21, 45, and 60 days frozen. Syringes were warmed to room temperature (RT) by gently rolling in hands. Three syringes of each formulation were assayed by stability-indicating HPLC per USP procedures. Assay results are the average of 5 injections of samples from each syringe upon return to RT and repeated for 3 separate syringes maintained at RT for 24 hours. Results: All formulations were stable out to 60 days frozen. Both of the piperacillin/tazobactam formulations were also stable when kept at refrigerated temperature for 9 days. Conclusion: Piperacillin/Tazobactam formulations can be stored frozen (−20°C) for up to 60 days with no appreciable loss. Cefuroxime and Vancomycin formulations can be stored frozen for up to 60 days. Both Piperacillin/Tazobactam formulations can be refrigerated for up to 9 days. Implementation of larger batch compounding coupled with frozen syringe storage and delivery could result in enhanced uniformity of composition and significant manpower savings.
- 25 November 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 57 (1) , 61-68
Stability of 4 Intravenous Drug Formulations in Prefilled Syringes Stored Frozen for Up to 60 Days
Purpose: Prefilled drug syringe use may reduce the cost of routine antibiotic drug delivery. Storage of prefilled syringes frozen (−20°C) or refrigerated (4°C-5°C), can optimize the use of robotic syringe filling systems if acceptable stability data is gathered per USP 797 standards. Methods: Four intravenous (IV) drug formulations were prepared from bulk standard solutions and filled into 10 mL syringes using an Intellifill© IV Robot. Formulations were Piperacillin (2.0 g) and Tazobactam (0.25 g) as 2.25 g in 10 mL; Piperacillin (3.0 g) and Tazobactam (0.375 g) as 3.375 g in 10 mL; Cefuroxime as 1.5 g in 11 mL; and Vancomycin as 1.0 g in 10 mL. Concentrations were assayed at “zero time,” and after 21, 45, and 60 days frozen. Syringes were warmed to room temperature (RT) by gently rolling in hands. Three syringes of each formulation were assayed by stability-indicating HPLC per USP procedures. Assay results are the average of 5 injections of samples from each syringe upon return to RT and repeated for 3 separate syringes maintained at RT for 24 hours. Results: All formulations were stable out to 60 days frozen. Both of the piperacillin/tazobactam formulations were also stable when kept at refrigerated temperature for 9 days. Conclusion: Piperacillin/Tazobactam formulations can be stored frozen (−20°C) for up to 60 days with no appreciable loss. Cefuroxime and Vancomycin formulations can be stored frozen for up to 60 days. Both Piperacillin/Tazobactam formulations can be refrigerated for up to 9 days. Implementation of larger batch compounding coupled with frozen syringe storage and delivery could result in enhanced uniformity of composition and significant manpower savings.
- 23 June 2019
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 43 (8) , 977-985
Plasma Citrulline Concentrations in Neonates With or Without Gastrointestinal Disease During Periods of Parenteral and Enteral Nutrition
Introduction: Citrulline is synthesized primarily in enterocytes. Retrospective work revealed higher plasma concentrations in patients without gastrointestinal (GI) disease than in those with GI disease, regardless of bowel resection, leading us to speculate whether it could be used as a marker of gut function prospectively. Our purpose was to analyze plasma citrulline in these patients, comparing a period of exclusive parenteral nutrition (PN) vs both PN and enteral nutrition (PN/EN).Methods: Premature neonates were included in this study. Plasma samples were collected during 2 periods, PN and PN/EN. They were classified into groups: patients without GI disease (Group 1), patients with GI disease without resection (Group 2), and patients with GI disease and resection (Group 3). Plasma was analyzed by high‐performance liquid chromatography and tandem mass spectrometry (LC‐MS/MS). Data were described as median with ranges.Results: Fifty patients were recruited for this study, from which 164 samples were obtained and analyzed by LC‐MS. Median plasma citrulline concentrations were 12.3 (5.6–39.4) µmol/L, 14.9 (6.8–39.8) µmol/L, and 10.8 (2.0–23.6) µmol/L for Groups 1, 2, and 3, respectively. After Bonferroni correction, only Group 3 had a significantly different median from the others. No differences were observed within periods of nutrition (PN vs PN/EN). Postconceptual age (PCA), among others, was assessed to determine differences for which the former demonstrated significance.Conclusion: Premature neonates with bowel resection had lower plasma citrulline concentrations, confirming its role as gut mass marker, though without differences during transitional feeding. PCA may affect expression of this protein.
- 23 June 2019
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 43 (8) , 977-985
Plasma Citrulline Concentrations in Neonates With or Without Gastrointestinal Disease During Periods of Parenteral and Enteral Nutrition
Introduction: Citrulline is synthesized primarily in enterocytes. Retrospective work revealed higher plasma concentrations in patients without gastrointestinal (GI) disease than in those with GI disease, regardless of bowel resection, leading us to speculate whether it could be used as a marker of gut function prospectively. Our purpose was to analyze plasma citrulline in these patients, comparing a period of exclusive parenteral nutrition (PN) vs both PN and enteral nutrition (PN/EN).Methods: Premature neonates were included in this study. Plasma samples were collected during 2 periods, PN and PN/EN. They were classified into groups: patients without GI disease (Group 1), patients with GI disease without resection (Group 2), and patients with GI disease and resection (Group 3). Plasma was analyzed by high‐performance liquid chromatography and tandem mass spectrometry (LC‐MS/MS). Data were described as median with ranges.Results: Fifty patients were recruited for this study, from which 164 samples were obtained and analyzed by LC‐MS. Median plasma citrulline concentrations were 12.3 (5.6–39.4) µmol/L, 14.9 (6.8–39.8) µmol/L, and 10.8 (2.0–23.6) µmol/L for Groups 1, 2, and 3, respectively. After Bonferroni correction, only Group 3 had a significantly different median from the others. No differences were observed within periods of nutrition (PN vs PN/EN). Postconceptual age (PCA), among others, was assessed to determine differences for which the former demonstrated significance.Conclusion: Premature neonates with bowel resection had lower plasma citrulline concentrations, confirming its role as gut mass marker, though without differences during transitional feeding. PCA may affect expression of this protein.
- 1 January 2016
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 21 (4) , 308-321
Calprotectin: Clinical Applications in Pediatrics
As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding. We surveyed all published studies in English of calprotectin in neonates, infants, children, and adolescents through February 2014. We will discuss calprotectin's basic properties and analysis such as characteristics, identification, presence in body fluids, and maturational development. In addition, calprotectin's use in inflammatory diseases exploring both GI and non-GI conditions will be evaluated and compared with other serum markers presently available. Finally, a summary of our findings and discussion of future work that could be undertaken in order to render calprotectin as a more useful monitoring tool to the medical research community will complete the review.
- 1 January 2016
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 21 (4) , 308-321
Calprotectin: Clinical Applications in Pediatrics
As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding. We surveyed all published studies in English of calprotectin in neonates, infants, children, and adolescents through February 2014. We will discuss calprotectin's basic properties and analysis such as characteristics, identification, presence in body fluids, and maturational development. In addition, calprotectin's use in inflammatory diseases exploring both GI and non-GI conditions will be evaluated and compared with other serum markers presently available. Finally, a summary of our findings and discussion of future work that could be undertaken in order to render calprotectin as a more useful monitoring tool to the medical research community will complete the review.
- 1 January 2015
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 20 (2) , 144-148
MMR Vaccine: When Is the Right Time for the Second Dose?
Outbreaks of measles have been reported over the past 5 years, particularly affecting children between the ages of 1 and 5 years. Most of these children are younger than the age recommended by the Advisory Committee on Immunization Practices for the second dose of measles-mumps-rubella (MMR) vaccine. Question may arise as to whether strict adherence to the scheduled second dose is required or whether there is opportunity for earlier immunization under special circumstances (e.g., traveling abroad, poor response as evidenced by titer levels). The history of measles, its characteristics, and its evolving past and current immunization policies will be reviewed, focusing on the original intent of the recommended schedule and presenting a case in which deviating from current practice could be justified.
- 1 January 2015
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 20 (2) , 144-148
MMR Vaccine: When Is the Right Time for the Second Dose?
Outbreaks of measles have been reported over the past 5 years, particularly affecting children between the ages of 1 and 5 years. Most of these children are younger than the age recommended by the Advisory Committee on Immunization Practices for the second dose of measles-mumps-rubella (MMR) vaccine. Question may arise as to whether strict adherence to the scheduled second dose is required or whether there is opportunity for earlier immunization under special circumstances (e.g., traveling abroad, poor response as evidenced by titer levels). The history of measles, its characteristics, and its evolving past and current immunization policies will be reviewed, focusing on the original intent of the recommended schedule and presenting a case in which deviating from current practice could be justified.